These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35603600)

  • 1. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.
    Goldberg RB; Orchard TJ; Crandall JP; Boyko EJ; Budoff M; Dabelea D; Gadde KM; Knowler WC; Lee CG; Nathan DM; Watson K; Temprosa M;
    Circulation; 2022 May; 145(22):1632-1641. PubMed ID: 35603600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.
    Aroda VR; Knowler WC; Crandall JP; Perreault L; Edelstein SL; Jeffries SL; Molitch ME; Pi-Sunyer X; Darwin C; Heckman-Stoddard BM; Temprosa M; Kahn SE; Nathan DM;
    Diabetologia; 2017 Sep; 60(9):1601-1611. PubMed ID: 28770322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
    Diabetes Prevention Program Research Group
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):866-75. PubMed ID: 26377054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.
    Perreault L; Pan Q; Mather KJ; Watson KE; Hamman RF; Kahn SE;
    Lancet; 2012 Jun; 379(9833):2243-51. PubMed ID: 22683134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
    ; Knowler WC; Fowler SE; Hamman RF; Christophi CA; Hoffman HJ; Brenneman AT; Brown-Friday JO; Goldberg R; Venditti E; Nathan DM
    Lancet; 2009 Nov; 374(9702):1677-86. PubMed ID: 19878986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium.
    Goldberg RB; Aroda VR; Bluemke DA; Barrett-Connor E; Budoff M; Crandall JP; Dabelea D; Horton ES; Mather KJ; Orchard TJ; Schade D; Watson K; Temprosa M;
    Circulation; 2017 Jul; 136(1):52-64. PubMed ID: 28476766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study.
    Herman WH
    Clin Diabetes Endocrinol; 2015; 1():9. PubMed ID: 28702228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of lifestyle and metformin interventions in DPP on bone density.
    Schwartz AV; Pan Q; Aroda VR; Crandall JP; Kriska A; Piromalli C; Wallia A; Temprosa M; Florez H;
    Osteoporos Int; 2021 Nov; 32(11):2279-2287. PubMed ID: 34086101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.
    Diabetes Prevention Program Research Group
    Diabetes Care; 2015 Jan; 38(1):51-8. PubMed ID: 25336746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
    Apolzan JW; Venditti EM; Edelstein SL; Knowler WC; Dabelea D; Boyko EJ; Pi-Sunyer X; Kalyani RR; Franks PW; Srikanthan P; Gadde KM;
    Ann Intern Med; 2019 May; 170(10):682-690. PubMed ID: 31009939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study.
    Luchsinger JA; Ma Y; Christophi CA; Florez H; Golden SH; Hazuda H; Crandall J; Venditti E; Watson K; Jeffries S; Manly JJ; Pi-Sunyer FX;
    Diabetes Care; 2017 Jul; 40(7):958-965. PubMed ID: 28500216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Intensive Lifestyle and Metformin Interventions With Frailty in the Diabetes Prevention Program Outcomes Study.
    Hazuda HP; Pan Q; Florez H; Luchsinger JA; Crandall JP; Venditti EM; Golden SH; Kriska AM; Bray GA
    J Gerontol A Biol Sci Med Sci; 2021 Apr; 76(5):929-936. PubMed ID: 33428709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
    Ratner R; Goldberg R; Haffner S; Marcovina S; Orchard T; Fowler S; Temprosa M;
    Diabetes Care; 2005 Apr; 28(4):888-94. PubMed ID: 15793191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of metformin and intensive lifestyle interventions on the incidence of kidney disease in adults in the DPP/DPPOS.
    Molitch ME; Tripputi M; Levey AS; Crandall JP; Dabelea D; Herman WH; Knowler WC; Orchard TJ; Schroeder EB; Srikanthan P; Temprosa M; White NH; Nathan DM;
    J Diabetes Complications; 2023 Sep; 37(9):108556. PubMed ID: 37607422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS).
    ; Hamman RF; Horton E; Barrett-Connor E; Bray GA; Christophi CA; Crandall J; Florez JC; Fowler S; Goldberg R; Kahn SE; Knowler WC; Lachin JM; Murphy MB; Venditti E
    Diabetes; 2015 Mar; 64(3):989-98. PubMed ID: 25277389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.
    Lee CG; Heckman-Stoddard B; Dabelea D; Gadde KM; Ehrmann D; Ford L; Prorok P; Boyko EJ; Pi-Sunyer X; Wallia A; Knowler WC; Crandall JP; Temprosa M; ;
    Diabetes Care; 2021 Dec; 44(12):2775-2782. PubMed ID: 34697033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
    Ipsen EØ; Madsen KS; Chi Y; Pedersen-Bjergaard U; Richter B; Metzendorf MI; Hemmingsen B
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013516. PubMed ID: 33210751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
    Diabetes Prevention Program Research Group
    Diabetes Care; 2012 Apr; 35(4):723-30. PubMed ID: 22442395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.